FINWIRES · TerminalLIVE
FINWIRES

RBC Upgrades ResMed to Outperform From Sector Perform, Raises Price Target to $262 From $244

By

ResMed (RMD) has an average rating of overweight and mean price target of $262.82, according to analysts polled by FactSet.

What else is happening in Research?